A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.
about
Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in ThailandPoxvirus vectors as HIV/AIDS vaccines in humansThe evolution of poxvirus vaccinesSelf-assembly of polyphosphazene immunoadjuvant with poly(ethylene oxide) enables advanced nanoscale delivery modalities and regulated pH-dependent cellular membrane activityProgress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccinesHuman immunodeficiency virus vaccine trialsPhase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidateThe role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralizationThe TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in miceCD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individualsDetection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system.Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia.Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection.Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens.A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assaysTargeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens.Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa.Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or PolyphosphazeneHuman immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein.Vaccinia virus vaccines: past, present and future.Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization.OX40:OX40L axis: emerging targets for improving poxvirus-based CD8(+) T-cell vaccines against respiratory virusesNeutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits.Tunable, biodegradable gold nanoparticles as contrast agents for computed tomography and photoacoustic imaging.Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection.Recombinant fowlpox virus vector-based vaccines: expression kinetics, dissemination and safety profile following intranasal delivery.Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infectionRational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011.HIV vaccine: it may take two to tango, but no party time yet.The US Military Commitment to Vaccine Development: A Century of Successes and Challenges.Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
P2860
Q21134955-E738A1E7-852D-486E-A076-5463F960112CQ26995078-DED97486-80F3-49E4-8405-374C32BBA7DDQ26995905-BA515AA0-F32D-46F8-B63E-2877691CA1FDQ28830111-C1C10279-FFD6-4EC3-B73B-62AFE9260D72Q30379200-530AE235-1490-4F15-AB66-30ED1FC9BE61Q30394227-2239566F-129A-4FD4-99C6-7DE1073BB111Q30424366-BB8F04D0-08D5-4EFC-B766-85A964C25893Q33749950-072002B1-0EAA-43E5-849F-B171FBEB97CBQ34234905-D3EEBD7A-9589-4DB5-86F0-09C7BF51052BQ34428899-64778BD8-D9FD-40AC-AD2F-4A89CADA9476Q34692141-F3D4AB12-4AC1-4F24-8ABE-1685C8B6DA8BQ35060140-E40787A8-FA8E-4777-B8C8-BFB8983FD62AQ35075505-B8B6EA59-BF1D-4417-8D24-2031C7A1728CQ35826728-4D5CBC7A-B973-444F-A55E-3BBD7069482FQ35878653-D8F90793-26F4-445F-9F64-C1F9F4742AC8Q35883032-5765674B-DE2F-4D5E-980B-CA0F61D10160Q36114395-D2FC4871-1361-4AB7-BF30-85337D8F2B61Q36294693-EAC12819-4AD2-47D5-829A-4A03C4FD53C0Q36363866-856F59F9-5E7F-409E-A8AC-49AA87F79630Q36382421-DDF5060F-F304-4739-ABC2-8DFF15E84716Q36498186-07C8D630-3E83-460B-8824-0B59505E771BQ36763303-90F741AC-DD8C-432A-961E-5F624A0662CBQ36931790-032060FA-1476-410F-989A-32948FBC0B13Q37033291-0E118CA1-043F-4E87-9711-0F88A8B6C5B2Q37343595-FBB6E197-2E64-4903-A80B-15AC680C0B52Q37404708-7E32297C-3ABD-419F-99A1-64D0A694EB1CQ37948126-8A2A84C5-165B-4837-A238-4BB0E397C686Q38356290-A95B6B1A-14B7-4F7F-B29E-6D02F1C4C6ECQ39670240-007D2BBE-FCD6-41D4-8620-E22CFE1E3D68Q39726192-DE1815F8-D48E-427A-BE2C-86341A679EE7Q40159913-93C9BB41-3DF7-47D8-9C31-F66BDC847CADQ40384316-8443F7B2-2F0F-44CA-892C-AE4F1D1F1F7EQ42386442-FE8B8A78-5C0E-48CB-BD8D-11981B2F0F9CQ42411962-C1396333-7C26-49D7-9415-40882017E474Q42590256-83A4ABCC-0A56-4129-A2A6-501CE049D3DDQ55432397-08CA31FF-283A-417D-A3F9-B94BFDF17033Q55447637-EE3B20A8-6D82-4981-92E4-10970B54D792
P2860
A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A phase 1/2 comparative vaccin ...... alent gp120 (CM235/SF2) boost.
@ast
A phase 1/2 comparative vaccin ...... alent gp120 (CM235/SF2) boost.
@en
type
label
A phase 1/2 comparative vaccin ...... alent gp120 (CM235/SF2) boost.
@ast
A phase 1/2 comparative vaccin ...... alent gp120 (CM235/SF2) boost.
@en
prefLabel
A phase 1/2 comparative vaccin ...... alent gp120 (CM235/SF2) boost.
@ast
A phase 1/2 comparative vaccin ...... alent gp120 (CM235/SF2) boost.
@en
P2093
P50
P1476
A phase 1/2 comparative vaccin ...... alent gp120 (CM235/SF2) boost.
@en
P2093
Arthur E Brown
Chirasak Khamboonruang
Chitraporn Karnasuta
John G McNeil
Lynn Baglyos
Mark S de Souza
Prasert Thongcharoen
Raphaelle El Habib
Robert M Paris
Sanjay Gurunathan
P356
10.1097/QAI.0B013E3181354BD7
P407
P577
2007-09-01T00:00:00Z